Artelo's fatty acid binding protein 5 inhibitor, art26.12, compares favorably to naproxen in an osteoarthritis pain study

Solana beach, calif., june 05, 2025 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced its presentation of new data at the british pain conference held in newport, wales, uk on june 3-5, 2025 (https://bpsasm.org/) that further validates the therapeutic potential of fatty acid binding protein (fabp) inhibitors in treating osteoarthritis (oa) pain.
ARTL Ratings Summary
ARTL Quant Ranking